Navigation Links
Vermillion to Present at Lazard Capital Markets Sixth Annual Healthcare Conference
Date:11/16/2009

FREMONT, Calif., Nov. 16 /PRNewswire-FirstCall/ -- Vermillion, Inc. (Pink Sheets: VRMLQ) today announced that Gail Page, Vermillion Executive Chairperson, will be presenting at the Lazard Capital Markets Sixth Annual Healthcare Conference in New York City.

The presentation is scheduled for Tuesday, November 17, 2009 at 5:10 p.m. Eastern Time.

About the OVA1 Test

The OVA1 Test is a qualitative serum test that combines the results of five immunoassays into a single numerical score. It is indicated for women who meet the following criteria: over age 18, ovarian adnexal mass present for which surgery is planned, and not yet referred to an oncologist. The test utilizes five well-established biomarkers --- Transthyretin (TT or prealbumin), Apolipoprotein A-1 (Apo A-1), Beta2-Microglobulin (Beta2M), Transferrin (Tfr) and Cancer Antigen 125 (CA 125 II) -- and a proprietary algorithm to determine the likelihood of malignancy in women with pelvic mass for whom surgery is planned.

Quest Diagnostics, which is a long-time investor in research and development of the OVA1 technology, has exclusive rights to offer the test to the clinical reference laboratory market in the U.S. for three years.

About Vermillion

Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, hematology, cardiology and women's health. Vermillion is based in Fremont, California. Additional information about Vermillion can be found on the Web at http://www.vermillion.com.

SOURCE Vermillion, Inc.


'/>"/>
SOURCE Vermillion, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Vermillion Receives Award From the Society of Gynecologic Oncologists
2. Vermillions Biomarkers Prove Beneficial in Identifying Women With Ovarian Cancer and Detecting Early-Stage Disease
3. Vermillion and the Ohio State University Report That Novel Diagnostic Test May Help Predict Risk for Relapse of TTP, A Serious Blood Disorder
4. Vermillion Files 510(k) Application With U.S. Food & Drug Administration for OVA1 Ovarian Tumor Triage Test
5. Vermillion Renews Strategic Alliance Agreement With Quest Diagnostics, Inc.
6. Vermillion Presents Critical Data From Its OVA1 Clinical Trial
7. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
8. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
9. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2017)... Research and Markets has announced the addition ... their offering. ... devices market to grow at a CAGR of 6.35% during the ... 2017-2021, has been prepared based on an in-depth market analysis with ... its growth prospects over the coming years. The report also includes ...
(Date:4/18/2017)... and BLOOMINGTON, Minn. , April ... IMMY ) ("Imprimis"), an ophthalmology-focused pharmaceutical company, ... Lens"), today announced the signing of a three-year ... Lens will deploy a dedicated sales team to ... the U.S., primarily focused in 13 states in ...
(Date:4/18/2017)... 2017 Research and Markets has announced ... Molecular Imaging Equipment and Radiopharmaceuticals Market, Forecast to 2023" ... ... revenues as well as growth in the number of unit ... to market participants that design and manufacture molecular imaging equipment. ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... April 25, 2017 , ... Vetoquinol USA® ... introducing Flexadin UCII, part of the EQUISTRO line, at this week’s Rolex Kentucky ... horses at the immunologic level. , The scientifically-developed Flexadin UCII supports the body’s ...
(Date:4/24/2017)... ... April 24, 2017 , ... Michael Vick announced his retirement earlier ... position. The former overall number one pick in the 2001 NFL Draft, to the ... the record for the most career rushing yards by a quarterback (6,109) and the ...
(Date:4/24/2017)... ... April 24, 2017 , ... NEPC Director Kevin ... of Education Research Award. The award honors scholars exemplary in their capacity to ... scholar who has demonstrated the capacity to deepen the public’s understanding and appreciation ...
(Date:4/24/2017)... Seattle, Washington (PRWEB) , ... April 24, 2017 , ... ... T-Fal OptiGrill, Oxiclean, Space Bag, Sonicare Toothbrush, Juiceman Juicer, and the George Foreman Grill ... than perhaps any other marketer in the last 25 years. , Now, due to ...
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... ... that they are seeking public support to bring their novel lifesaving device for ... wearable device packed with medical-grade sensors, specially designed to read a child’s vital ...
Breaking Medicine News(10 mins):